We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
-9.41%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$982M
AUM Growth
+$21.4M
Cap. Flow
+$184M
Cap. Flow %
18.72%
Top 10 Hldgs %
37.6%
Holding
143
New
43
Increased
40
Reduced
5
Closed
15

Top Buys

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$29.1M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$19.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$15.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$15.4M
5
TDOC icon
Teladoc Health
TDOC
+$12.2M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$24.5M
2
MOR
MorphoSys AG American Depositary Shares
MOR
+$14.5M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$9.44M
4
NTLA icon
Intellia Therapeutics
NTLA
+$5.5M
5
BLUE
bluebird bio
BLUE
+$3.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.92%
2 Technology 1.53%
3 Real Estate 0.71%
4 Communication Services 0.66%
5 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
51
DELISTED
Merus
MRUS
$5.92M 0.6%
+100,000
New +$4.84M
META icon
52
Meta Platforms (Facebook)
META
$1.51T
$5.75M 0.59%
11,396
+1,396
+14% +$679K
GPCR icon
53
Structure Therapeutics
GPCR
$3.78B
$5.67M 0.58%
144,500
+44,500
+45% +$1.83M
MRNS
54
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5.62M 0.57%
+4,800,000
New +$12M
CYTK icon
55
Cytokinetics
CYTK
$10.4B
$5.42M 0.55%
100,000
– –
ONC
56
BeOne Medicines Ltd
ONC
$39.4B
$5.28M 0.54%
37,000
– –
DSGN icon
57
Design Therapeutics
DSGN
$876M
$4.96M 0.51%
1,480,975
– –
BCRX icon
58
BioCryst Pharmaceuticals
BCRX
$2.4B
$4.94M 0.5%
800,000
– –
BHVN icon
59
Biohaven
BHVN
$2.21B
$4.86M 0.49%
140,000
– –
ARVN icon
60
Arvinas
ARVN
$572M
$4.79M 0.49%
180,000
– –
ARE icon
61
Alexandria Real Estate Equities
ARE
$8.56B
$4.68M 0.48%
+40,000
New +$4.77M
OKUR
62
OnKure Therapeutics
OKUR
$168M
$4.52M 0.46%
299,626
-74
-0% -$1.25K
LQDA icon
63
Liquidia Corp
LQDA
$8.02B
$4.2M 0.43%
350,000
+200,000
+133% +$2.65M
LNTH icon
64
Lantheus
LNTH
$6.59B
$4.01M 0.41%
50,000
– –
IOVA icon
65
Iovance Biotherapeutics
IOVA
$2.87B
$4.01M 0.41%
500,000
– –
APGE icon
66
Apogee Therapeutics
APGE
$10.2B
$3.94M 0.4%
100,000
– –
ENTA icon
67
Enanta Pharmaceuticals
ENTA
$400M
$3.89M 0.4%
300,000
– –
SEER icon
68
Seer Inc
SEER
$120M
$3.86M 0.39%
2,300,000
+1,625,875
+241% +$3.04M
NKTX icon
69
Nkarta
NKTX
$172M
$3.25M 0.33%
550,000
– –
BOLT icon
70
Bolt Biotherapeutics
BOLT
$7.78M
$2.86M 0.29%
190,639
+19,639
+11% +$387K
LONA
71
LeonaBio Inc
LONA
$72.1M
$2.79M 0.28%
105,272
+20,000
+23% +$472K
GMAB icon
72
Genmab
GMAB
$19.5B
$2.51M 0.26%
100,000
– –
INBX icon
73
Inhibrx
INBX
$1.3B
$2.37M 0.24%
+167,500
New +$2.62M
FATE icon
74
Fate Therapeutics
FATE
$326M
$2.3M 0.23%
700,000
– –
IPSC icon
75
Century Therapeutics
IPSC
$361M
$2.29M 0.23%
900,000
– –
1 2
3
4 5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Tang Capital Management held 143 positions worth $982M, up 2.2% from $960M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tang Capital Management deployed $184M of net new capital in Q2 2024, opening 43 new positions and adding to 40 existing holdings. Its largest new stake was Dynavax Technologies: 2,500,000 shares worth $28.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Technology and Real Estate.

On the sell side, the largest reduction was Quince Therapeutics, an estimated $1.31M trimmed.

  • Tang Capital Management's largest Q2 2024 buy was Dynavax Technologies: 2,500,000 shares worth $28.1M.
  • Tang Capital Management added most to ANI Pharmaceuticals in Q2 2024, an estimated $19.5M increase.
  • Tang Capital Management's biggest Q2 2024 reduction was Quince Therapeutics, cutting an estimated $1.31M.
  • Tang Capital Management fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $24.5M.
  • Tang Capital Management's ten largest holdings make up 38% of its $982M portfolio in Q2 2024.
  • Tang Capital Management opened 43 new positions and closed 15 in Q2 2024.
  • Tang Capital Management's portfolio value rose 2.2% quarter-over-quarter to $982M.

Based on Tang Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.